Lexaria's DehydraTECH-Semaglutide Shows Significant Reduction in Adverse Events Compared to Rybelsus in Phase 1b Study
TL;DR
Lexaria Bioscience Corp.'s DehydraTECH-semaglutide shows a 36.5% reduction in side effects compared to Rybelsus®, offering a competitive edge in GLP-1 treatments.
Lexaria's study demonstrates DehydraTECH-semaglutide's mechanism reduces gastrointestinal side effects by 43.5% and overall side effects by 36.5% versus Rybelsus® in an 8-week interim analysis.
DehydraTECH-semaglutide's reduced side effects could improve patient adherence to treatment, enhancing quality of life for millions managing diabetes and obesity.
Lexaria's innovative DehydraTECH technology not only cuts side effects significantly but also hints at a future where oral GLP-1 treatments surpass injectables in safety.
Found this article helpful?
Share it with your network and spread the knowledge!
Lexaria Bioscience Corp. has reported encouraging interim results from its phase 1b study, GLP-1-H24-4, showcasing the potential of DehydraTECH-semaglutide to reduce adverse effects significantly compared to the currently approved oral GLP-1 medication, Rybelsus®. The study, focusing on the safety and tolerability of DehydraTECH-GLP-1 formulations, found a 36.5% reduction in overall adverse events and a 43.5% decrease in gastrointestinal side effects with DehydraTECH-semaglutide versus Rybelsus®.
Richard Christopher, CEO of Lexaria, highlighted the significance of these findings, noting the superiority of DehydraTECH in minimizing unwanted side effects, which could lead to better patient compliance and treatment outcomes. The study's interim data also suggests that DehydraTECH-tirzepatide may offer a reduction in adverse events by as much as half compared to injectable tirzepatide, based on comparisons with historical data from injected tirzepatide trials.
While the interim results are promising, Lexaria cautions that the full implications of these findings will only be clear upon completion of the study, with final results expected by the end of 2025. The company's DehydraTECH technology continues to demonstrate its potential to enhance drug delivery, offering hope for improved treatment protocols for patients requiring GLP-1 medications.
Curated from NewMediaWire
